The Dealing Totals on the Rule 38.5 report issued this morning were incorrect. The correct totals are shown on this
report.
Form 38.5 (b)
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS
WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS
BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
(Rule 38.5(b) of the Takeover Code)
1. KEY INFORMATION
Name of exempt principal Barclays Capital Securities Limited
trader
Company dealt in Melrose Plc
Class of relevant security ORD GBP0.002
to which the dealings being
disclosed relate (Note 1)
Date of dealing 27/03/2008
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
(a) Interests and short positions (following dealing) in the class of relevant
security dealt in (Note 2)
Long Short
Number (%) Number (%)
(1) Relevant securities
12,365 0.01% 84,959 0.06%
(2) Derivatives (other than
options) 84,772 0.06% 12,365 0.01%
(3) Options and agreements
to purchase/sell
Total 97,137 0.07% 97,324 0.07%
(b) Interests and short positions in relevant securities of the company, other
than the class dealt in (Note 2)
Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than
options)
(3) Options and agreements
to purchase/sell
Total
(c) Rights to subscribe (Note 2)
Class of relevant security: Details
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of Price per
securities unit (Note
4)
Purchase 670 1.3676
Sale 5,700 1.4257
Sale 5,836 1.3972
Totals
Total Sale: 11,536
Total Purchase: 670
(b) Derivatives transactions (other than options)
Product Long/short Number of Price per
name, (Note 5) securities unit
(Note 6) (Note 4)
e.g. CFD
CFD Long 5836 1.3972
CFD Long 5700 1.4256
CFD Short 670 1.3676
Totals
Total Long: 11,536
Total Short: 670
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Product name, Writing, Number of Exercise Type, e.g. Expiry Option money
e.g. call selling, securities to price American, date paid/received
option purchasing, which the option European etc. per unit (Note 4)
varying etc. relates (Note 6)
(ii) Exercising
Product name, e.g. call Number of securities Exercise price per unit
option (Note 4)
(d) Other dealings (including new securities) (Note 3)
Nature of transaction Details Price per unit (if
(Note 7) applicable) (Note 4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the
person disclosing and any other person relating to the voting rights of
any relevant securities under any option referred to on this form or
relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is
referenced. If none, this should be stated.
Is a Supplemental Form 38.5(b) attached? (Note 8) NO
Date of disclosure 28/03/08
Contact name Barclays Plc
Telephone number 0207 116 2913
Name of offeree/offeror with which FKI Plc
connected
Nature of connection (Note 9) ADVISOR
Notes
The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.